Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10329699 | 1.00 | LMNA (0.51) | LMNATP53CYP3A4GRM2GRM3 | |
| SCHEMBL21243359 | 0.84 | TP53 (0.60) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL12670574 | 0.83 | TP53 (0.55) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL11282546 | 0.81 | LMNA (0.47) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL28475889 | 0.81 | LMNA (0.47) | LMNAGRM2GRM3SLC1A3SLC1A2 | |
| SCHEMBL21243331 | 0.79 | TP53 (0.46) | LMNATP53CYP3A4GRM2GRM3 | |
| SCHEMBL28376921 | 0.78 | LMNA (0.51) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL14428796 | 0.76 | CYP3A4 (0.51) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL29625800 | 0.76 | TP53 (0.47) | LMNATP53CYP3A4SLC1A3SLC1A2 | |
| SCHEMBL11281608 | 0.76 | LMNA (0.53) | LMNATP53CYP3A4SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222240-B2 | Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-17 | — | — | US | disclosed |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-02 | — | — | US | disclosed |
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045590-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | CYP27A1, CYP11B2, CYP11B1 | LMNA 3703/4885TP53 4693/4885CYP3A4 123/4885 |
| US-20090088474-A1 | USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME | FFAR1, FFAR2, FFAR3 | LMNA 3135/4885TP53 4852/4885CYP3A4 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.